Panel Discussion | Thrombus Management and Anticoagulation

Sunday, March 8, 2026

3:50 PM - 4:15 PM EST

Location: Lincoln

Moderator(s)

Usman Baber, MD, MS

Professor of Medicine
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States

Disclosure(s): AstraZeneca Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scietific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
David J. Cohen, MD, FSCAI

Director of Clinical and Outcomes Research
Cardiovascular Research Foundation
New York, New York, United States

Disclosure(s): Zoll Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Luis Ortega-Paz, MD, PhD

Assistant professor
University of Florida College of Medicine-Jacksonville
Jacksonville, Florida, United States

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

SA

Surendra Avula, MD, FACC

Medical center Clinical Assocaite professor of medicine /Cardiology. University of illinois
Advocate Christ medical center/ Palos North Western Medical center
Orland park, Illinois, United States

Disclosure(s): No financial relationships to disclose
Alfredo E. Rodriguez, MD,PhD

Director Cardiac Unit
Otamendi Hospital
CABA, Buenos Aires, Argentina

Disclosure information not submitted.
Marc Cohen, MD

Chair of Medicine
Newark Beth Israel Med Ctr
Philadelphia, Pennsylvania, United States

Disclosure(s): BSC, Amgen, BCRI, PERC, NAMSA, BMS, Janssen, Regeneron: Grant/Research Support (Ongoing)
C. Michael Gibson, MD

Professor of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Disclosure(s): Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)

Disclosure(s):

Usman Baber, MD, MS: AstraZeneca Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boston Scietific: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

David J. Cohen, MD, FSCAI: Zoll Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Luis Ortega-Paz, MD, PhD: No financial relationships to disclose

Surendra Avula, MD, FACC: No financial relationships to disclose

Marc Cohen, MD: BSC, Amgen, BCRI, PERC, NAMSA, BMS, Janssen, Regeneron: Grant/Research Support (Ongoing)

C. Michael Gibson, MD: Amgen, Chiesi, Angel/Avertix Medical, Anthos Therapeutics, Janssen Pharmaceuticals, Johnson & Johnson Corporation, Bayer Corporation, Corsear, MashUp MD, Bioclinica, MD Magazine, Boehringer Ingelheim, Merck, Boston Clinical Research Institute, MjHeal: Consulting Fees (e.g., advisory boards) (Ongoing); HeartBeam, nference, Flow Therapy, Celecor, Fortress Biotech, TribeMD (Co-Founder), Generable and Lexaria: Stock Options [in privately held companies] (Ongoing); Johnson & Johnson Corporation, CSL Behring, SCAD Alliance, NACAM Trial (Sub-award - 5R01HL151996-05), and Janssen Pharmaceuticals.: Grant/Research Support (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing)